The National Unified Procurement Company (NUPCO) of Saudi Arabia has officially announced the winning results of the centralized procurement project for the three-year outsourced testing services of public hospitals. Genalive, the Saudi joint venture of BGI Genomics, has won a contract worth 950 million yuan (RMB) by virtue of its globally leading technological strength and localized service capabilities. This is the largest outsourced testing service order that Genalive has obtained in Saudi Arabia so far, and it will provide strong support for improving the local level of precision medicine services.

In the previous global COVID-19 prevention and control work, BGI Genomics has carried out all-round cooperation with Saudi Arabia, providing it with a full set of nucleic acid testing solutions for the novel coronavirus and a virus sequencing platform, helping to establish the monitoring capability of mutant strains, and providing solid support for the local public health construction. This centralized procurement in Saudi Arabia is the outsourced testing bid with the largest amount and the most testing items in NUPCO's history, covering multiple methodologies such as NGS (Next Generation Sequencing), pathology, cytogenetics, and Sanger sequencing. It includes 930,000 testing services and will provide a comprehensive solution for 83 public hospitals across Saudi Arabia. (This article is from the official website of Seetao.com, www.seetao.com. No reprinting is allowed without permission. Otherwise, legal liability will be pursued. If reprinting, please indicate Seetao.com + the original text link.) Editor of the Strategic Column of Seetao.com / Yin Shiqian